Fused Pyrimidine Compounds Overcoming HIV Drug Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-nucleoside reverse transcriptase inhibitors (NNRTIs) used in HIV treatment face challenges due to drug resistance mutations in the HIV virus, necessitating the development of more potent NNRTIs.
Innovation Solution
Development of compounds of Formula (I) and their pharmaceutically acceptable salts, which are used in compositions and formulations to inhibit reverse transcriptase in subjects, thereby treating or preventing HIV infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current NNRTIs are used for HIV treatment, then treatment efficacy is achieved, but drug resistance mutations develop
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of NNRTI compounds through various substitutions at positions R1, R2, R3, R4, and R5. These structural parameter changes create new compounds with potentially improved binding affinity and resistance profiles while maintaining the core pyrimidine inhibitor mechanism
Solution Approach 2:
The patent employs composite material principles by combining the pyrimidine core structure with various substituent groups (aryl, heteroaryl, alkyl, halogen, etc.) to create composite molecular structures. This allows optimization of both efficacy and resistance properties through careful selection of substituent combinations
2Reliability
If new NNRTI compounds are developed to overcome resistance, then potency may be improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the NNRTI molecule into distinct functional regions: a core pyrimidine structure and variable substituent positions (R1-R5). This modular approach allows independent optimization of different regions to achieve potency while managing structural complexity through systematic variation of discrete substituents
Data Source
AI summary
Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.